Q32 Bio Inc. (NASDAQ:QTTB) Stock Holdings Increased by Barclays PLC

Barclays PLC boosted its stake in shares of Q32 Bio Inc. (NASDAQ:QTTB) by 105.2% during the third quarter, HoldingsChannel.com reports. The firm owned 10,443 shares of the company’s stock after acquiring an additional 5,353 shares during the period. Barclays PLC’s holdings in Q32 Bio were worth $465,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Values First Advisors Inc. purchased a new position in shares of Q32 Bio during the 3rd quarter valued at $33,000. BNP Paribas Financial Markets boosted its position in Q32 Bio by 199.1% during the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock valued at $58,000 after purchasing an additional 864 shares during the last quarter. Rhumbline Advisers grew its stake in Q32 Bio by 11,681.5% in the second quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock valued at $137,000 after purchasing an additional 7,593 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Q32 Bio in the 3rd quarter worth about $159,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Q32 Bio during the 2nd quarter worth about $265,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Stock Performance

Shares of QTTB opened at $3.45 on Friday. The company has a market capitalization of $42.02 million, a PE ratio of -0.24 and a beta of -0.46. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio Inc. has a one year low of $3.02 and a one year high of $53.79. The company’s fifty day moving average price is $25.33 and its 200 day moving average price is $32.40.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Leerink Partners reissued a “market perform” rating and issued a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Guggenheim downgraded shares of Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Wells Fargo & Company restated an “equal weight” rating and set a $16.00 price target (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Oppenheimer decreased their price objective on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, BMO Capital Markets cut their target price on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.